FDA Approves Once-Weekly Saphnelo Autoinjector for Lupus

April 2026

By Jason Laday Fact checked by Shenaz Bagha

Key takeaways:

• Anifromulab had previously been approved in IV form for systemic lupus erythematosus.
• The decision to approve the Saphnelo Pen was based on results from the TULIP-SC trial.

The FDA has approved a self-administered autoinjector form of anifrolumab for the treatment of systemic lupus erythematosus, according to press release from the manufacturer.

The anifrolumab (Saphnelo, AstraZeneca) autoinjector, dubbed the Saphnelo Pen, has been approved for once-weekly use alongside standard therapy. The drug, a type I interferon receptor antagonist, was first approved in IV form for SLE in 2021.

“The FDA approval of the anifrolumab autoinjector is a monumental step forward in lupus management, literally bringing transformative care right to the patient’s doorstep,” Shivani Garg, MD, PhD, director of the Yale Lupus Clinical Research Program and co-director of the Yale Lupus Program at the Yale School of Medicine, told Healio.

“For years, I have had patients struggling with debilitating SLE and cutaneous lupus erythematosus who would benefit from this targeted therapy, anifrolumab,” she added. “Yet, ultimately, they had to decline anifrolumab simply because they cannot manage the logistical burden of regular IV infusion appointments or afford the cost to cover for infusion appointments. By offering a self-administered option, we are removing a massive barrier to access, giving our patients options, reducing their daily disruptions and putting the power of their treatment directly into their own hands.”

Continue reading from HERE